ClinicalTrials.gg

Program

saruparib

Also written as “Saruparib”, “Saruparib (AZD5305)” and “AZD5305”.

Its studies are mostly in Prostatic Neoplasms · Ovarian Neoplasms · Breast Neoplasms · Neoplasm Metastasis · Neoplasms, led by AstraZeneca.

Furthest: phase 3, since Oct 17, 202314 company-led studies, 11 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca1411 open or runningphase 3since Oct 17, 2023Jul 30, 2014Dec 31, 2026phase 1 · NCT06713369
  • Named in AstraZeneca’s own pipeline as saruparib, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: fortrea, parexel and Bayer.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Jul 30, 2014.

  1. Oct 26, 2020Phase 2 study in Ovarian NeoplasmsNCT04644068 · 702 enrolled · United States, Australia, Canada and more
  2. Oct 13, 2021Phase 2 study in Breast NeoplasmsNCT05123482 · 460 planned · United States, Australia, Belgium and more
  3. Apr 19, 2022Phase 2 study in Prostatic NeoplasmsNCT05367440 · 174 enrolled · United States, Australia, Italy and more
  4. Oct 7, 2022Phase 1 study in NeoplasmsNCT05573724 · 16 enrolled · Moldova, Republic of, Romania
  5. May 16, 2023Phase 1 study in Prostatic NeoplasmsNCT05938270 · 113 enrolled · United States, Australia, Canada and more
  6. Oct 17, 2023Phase 3 study in Prostatic NeoplasmsNCT06120491 · 1,898 enrolled · United States, Australia, Austria and more
  7. Mar 25, 2024Phase 3 study in Advanced Breast CancerNCT06380751 · 788 planned · United States, Argentina, Australia and more
  8. Jul 30, 2024Phase 1 study in Neoplasm MetastasisNCT06713369 · 8 planned · United Kingdom
  9. Mar 21, 2025Phase 1 study in Advanced Solid MalignanciesNCT06899061 · 41 enrolled · Bulgaria, Moldova, Romania
  10. Apr 30, 2025Phase 3 study in Prostatic NeoplasmsNCT06952803 · 700 planned · United States, Argentina, Australia and more
  11. Jun 24, 2025Phase 2 study in Ovarian NeoplasmsNCT07060365 · Spain
  12. Feb 26, 2026Phase 2 study in Solid TumoursNCT07446855 · 180 planned · United States, Australia, Japan and more
  13. Jul 14, 2026Phase 3 study in Prostatic NeoplasmsNCT07711002 · 1,330 planned · United States, Austria, Brazil and more
  14. Nov 12, 2026Primary completion moved from 2026-10-02 to 2026-12-31Date moved laterphase 1 · +3 months · NCT06713369

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Neoplasm MetastasisNCT06713369
  2. May 28, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT04644068
  3. Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05123482
  4. Sep 30, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT06120491

TargetBeta

PARP1 →PARP2 →read by rule
“An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, saruparib selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks vi…”NCIt, read by Claude
“Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
olaparibruleAstraZenecaphase 478
niraparibruleGlaxoSmithKlinephase 443
senaparibruleimpact-therapeutics-incphase 212
nesuparibruleJeil Pharmaceuticalphase 24

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07711002Prostatic Neoplasms · United States, Austria, Brazil and more3RecruitingMay 30, 20311,330
NCT07446855Solid Tumours · United States, Australia, Japan and more2RecruitingMar 29, 2030180
NCT07060365Ovarian Neoplasms · Spain2WithdrawnDec 19, 20250
NCT06952803Prostatic Neoplasms · United States, Argentina, Australia and more3RecruitingMar 31, 2033700
NCT06899061Advanced Solid Malignancies · Bulgaria, Moldova, Romania1Active, not recruitingFeb 3, 202641
NCT06713369Neoplasm Metastasis · United Kingdom1RecruitingDec 31, 20268
NCT06380751Advanced Breast Cancer · United States, Argentina, Australia and more3RecruitingDec 18, 2029788
NCT06120491Prostatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingSep 30, 20271,898
NCT05938270Prostatic Neoplasms · United States, Australia, Canada and more1CompletedJun 15, 2026113
NCT05573724Neoplasms · Moldova, Republic of, Romania1CompletedApr 17, 202316
NCT05367440Prostatic Neoplasms · United States, Australia, Italy and more2Active, not recruitingApr 11, 2031174
NCT05123482Breast Neoplasms · United States, Australia, Belgium and more2RecruitingSep 29, 2027460
NCT04644068Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingMay 28, 2027702
NCT02264678Ovarian Neoplasms · United States, France, South Korea and more1Active, not recruitingMar 4, 2025358

How it is read

Names in the registry

  • “Saruparib”, 6 entries
  • “Saruparib (AZD5305)”, 3 entries
  • “AZD5305”, 3 entries
  • “[14C]-AZD5305 microtracer”, 1 entry
  • “[14C]-AZD5305 (therapeutic dose)”, 1 entry

Codes read as this program: AZD5305.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.